Literature DB >> 6957657

Dose-response studies with nitrosoheptamethyleneimine and its alpha-deuterium-labeled derivative in F344 rats.

W Lijinsky, M D Reuber, T S Davies, C W Riggs.   

Abstract

A dose-response study of the carcinogenicity of nitrosoheptamethyleneimine (N-HEP) in inbred F344 male and female rats was performed by administration of the nitrosamine at several concentrations in drinking water to groups of 20 rats. The concentrations differed by a factor of nearly 2.5 and ranged from 1.0 to 100 mg/liter. The duration of treatment was 13, 25, 50, or 100 weeks, after which the animals were allowed to die naturally of tumors induced. In most treated groups the incidence of tumors of the upper gastrointestinal tract approached 100%. However, at the higher doses there was an inverse relationship between total dose and survival time of the rats. Matched treatment of groups of rat with N-HEP labeled with deuterium in the alpha positions resulted in longer survival. The slower action of the deuterium-labeled compound, as measured by a lower rate of death from tumors, suggests that cleavage of a carbon-hydrogen bond at an alpha position is a rate-limiting step in carcinogenesis by N-HEP in rats.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6957657

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  3 in total

Review 1.  Structure-activity relations in carcinogenesis by N-nitroso compounds.

Authors:  W Lijinsky
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 2.  Deuterium isotope effects in carcinogenesis by N-nitroso compounds.

Authors:  W Lijinsky
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

3.  A carcinogenic potency database of the standardized results of animal bioassays.

Authors:  L S Gold; C B Sawyer; R Magaw; G M Backman; M de Veciana; R Levinson; N K Hooper; W R Havender; L Bernstein; R Peto
Journal:  Environ Health Perspect       Date:  1984-12       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.